Empathy is essential for being human for understanding and sharing other people’s affective and mood, including pain. Pain empathy is a mental ability that allows one person to understand another person’s pain and how to respond to that person effectively. The same neural structures as pain and empathy have recently been found to be involved in functional magnetic resonance imaging (fMRI) studies. When someone witnesses other’s pain, besides the visual cortex, various parts of the nervous system activate, including the neural network of empathy. Empathy includes not only pain but also other emotions, such as anger, sadness, fear, distress. These findings raised beg the question of whether empathy for pain is unique in its neural correlates. It is essential to know for revealing empathy is a specific context or in a state of chronic pain, depression or anxiety disorders. Because of this, pain empathy has been the central focus of empathy research in social neuroscience and other related fields, highlighting the importance of empathy for pain in daily life. Considering how pain plays a crucial role in the quality of life, determining its network and neurocognitive correlations in the empathy processing may provide a novel therapeutic approach for pain management. This area, which is still under investigation, can provide new information about pain. Under the recent studies and hypothesis, we have aimed to clarify the term of pain empathy, its components, and its neural correlates.
Aim: We investigated the connection between D vitamin and factors such as the type of antiepileptic agent, patient age and gender.Methods: This retrospective case-control study enrolled a total of 301 participants, including 141 epilepsy patients with (n= 120) without drug (n=21) regimens followed up in Alanya Alaaddin Keykubat University neurology outpatient clinic and 160 healthy individuals who applied to the neurology outpatient clinic for different reasons from January 2018 to January 2021. Demographics, detailed history, use of medications, duration of antiepileptic use, plasma 25-hydroxy Vitamin D and calcium levels were determined.Results: The mean level of Vitamin D was 15.46 in the epilepsy group and 16.95 in the control group. Level of D Vitamine did not differ significantly by groups (p>0.05). There were no significant relationship regarding age and vitamin D levels in both groups while decreased Vitamin D levels were detected epileptic women. Vitamin D level was below 20 in 69.6% of healthy control group, 78.9% of carbamazepine users, 62.5% of lacosamide users, all lamotrigine users, 66.7% of levatiracetam users, and 72.4% of sodium valproate users. No significant connection were detected between levels of Vitamin D and the drug used (p>0.05) while a significant association was confirmed only between calcium levels and carbamazepine (p<0.05).Conclusion: Vitamin D and calcium levels can be found to be low in antiepileptic users; however, except for the calcium levels in the carbamazepine group, this decrease does not constitute a significant difference.
Aim: To investigate the clinical characteristics and cerebral FDG PET metabolisms of dementia patients who were also diagnosed with epilepsy and compare the differences with pure Alzheimer dementia patients.Methods: In this case-control study, a total of 14 patients, 7 patients with pure Alzheimer disease as a control group and 7 age and gender-matched patients with Alzheimer disease and concomitant epilepsy as a study group, were included. Detailed neurocognitive battery and brain fludeoxyglucose positron emission tomography (FDG PET-CT) were performed for all subjects.Results: In comparison of neurocognitive test scores, there was no significant difference between the study and control groups. However, geriatric depression scale scores were significantly lower in study group than the controls (p= 0.026). In cerebral FDG-PET CT profiles of subjects we detected significantly lower metabolism in left and right cerebellum, left lentiform nucleus, right thalamus and vermis in the study group (p=0.008, p=0.023, p=0.003, p=0.002, p=0.002, respectively). In the right parietotemporal cortex and right and left associative visual cortex, we found higher metabolism in the study group than controls (p=0.023, p=0.012, p=0.003, respectively).Conclusion: Epileptic patients with Alzheimer’s dementia may have distinct clinical and metabolic profiles, than pure Alzheimer’s disease patients. Even if there is no difference in the neurocognitive clinical scores of the patients, depression and related functional abnormalities may be a biomarker of epileptic AD.